- Citations, last 5 years
- 248
- Works, last 5 years
- 4
- h-index
- 45
- Scientists listed
- 1
- Grants since 2016
- 16
Grants received
2024–2026 · grant · SB1
Advancing the commercialization readiness of nanoparticle-based immunotherapy for cancer treatment
Worapol Ngamcherdtrakul · PDX Pharmaceuticals (United States) · funded by National Institutes of Health
2024–2026 · grant · SB1
Advancing the commercialization readiness of nanoparticle-based immunotherapy for cancer treatment
Worapol Ngamcherdtrakul · PDX Pharmaceuticals (United States) · funded by National Institutes of Health
2023–2026 · research · R44
PLK1 and EGFR targeted nanoconstruct as a monotherapy and a radiation sensitizer for lung cancer
Worapol Ngamcherdtrakul · PDX Pharmaceuticals (United States) · funded by National Institutes of Health
2023–2024 · research · R44
PLK1 and EGFR targeted nanoconstruct as a monotherapy and a radiation sensitizer for lung cancer
Worapol Ngamcherdtrakul · PDX Pharmaceuticals (United States) · funded by National Institutes of Health
2023–2027 · research · R44
PLK1 and EGFR targeted nanoconstruct as a monotherapy and a radiation sensitizer for lung cancer
Worapol Ngamcherdtrakul · PDX Pharmaceuticals (United States) · funded by National Institutes of Health
2021–2024 · research · R44
Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer
Worapol Ngamcherdtrakul · PDX Pharmaceuticals (United States) · funded by National Institutes of Health
2021–2025 · research · R44
Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer
Worapol Ngamcherdtrakul · PDX Pharmaceuticals (United States) · funded by National Institutes of Health
2021–2024 · research · R44
In Situ Tumor Vaccination with a Nano-oligo Therapeutic to Induce Whole-body Antitumor Immune Response
Worapol Ngamcherdtrakul · PDX Pharmaceuticals (United States) · funded by National Institutes of Health
2021–2023 · research · R44
In Situ Tumor Vaccination with a Nano-oligo Therapeutic to Induce Whole-body Antitumor Immune Response
Worapol Ngamcherdtrakul · PDX Pharmaceuticals (United States) · funded by National Institutes of Health
2021–2022 · research · R44
Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer
Worapol Ngamcherdtrakul · PDX Pharmaceuticals (United States) · funded by National Institutes of Health
2019–2020 · research · R44
Supplement grant for R44CA217534: Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer
Worapol Ngamcherdtrakul · PDX Pharmaceuticals (United States) · funded by National Institutes of Health
2017–2019 · research · R43
Development of topical formulation of siRNA-nanoparticle for treating skin diseases
Worapol Ngamcherdtrakul · PDX Pharmaceuticals (United States) · funded by National Institutes of Health
2017–2021 · research · R44
Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer
Joe W. Gray · PDX Pharmaceuticals (United States) · funded by National Institutes of Health
2017–2020 · research · R44
Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer
Joe W. Gray · PDX Pharmaceuticals (United States) · funded by National Institutes of Health
2017–2019 · research · R44
Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer
Joe W. Gray · PDX Pharmaceuticals (United States) · funded by National Institutes of Health
2017–2018 · research · R44
Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer
Joe W. Gray · PDX Pharmaceuticals (United States) · funded by National Institutes of Health